Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Placebo-Controlled Study of Perifosine in Combination With Single Agent Chemotherapy for Metastatic Cancer Patients.

Next Previous
X
Search
Trial Profile

A Randomized Placebo-Controlled Study of Perifosine in Combination With Single Agent Chemotherapy for Metastatic Cancer Patients.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 16 Mar 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Perifosine (Primary) ; Capecitabine; Docetaxel; Doxorubicin; Gemcitabine; Irinotecan; Paclitaxel; Pemetrexed
  • Indications Advanced breast cancer; Colorectal cancer; Head and neck cancer; Non-small cell lung cancer; Ovarian cancer; Prostate cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 03 Oct 2011 Final results in colorectal cancer patients published in the Journal of Clinical Oncology.
    • 02 Jun 2009 Interim results in colorectal cancer patients presented at the 45th Annual Meeting of the American Society of Clinical Oncology.
    • 07 Apr 2008 Status changed from recruiting to in progress, according to ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top